Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma

被引：0

作者：

Trneny, Marek

Lamy, Thierry

Walewski, Jan Andrzej

Belada, David

Mayer, Jiri

Radford, John A.

Jurczak, Wojciech

Morschhauser, Franck

Alexeeva, Julia

Rule, Simon

Biyukov, Tsvetan Nikolov

Patturajan, Meera

Bravo, Marie-Laure Casadebaig

Cabecadas, Jose

Arcaini, Luca

机构：

[1] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic

[2] Hop Pontchaillou, Dept Hematol, Rennes, France

[3] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Dept Lymphoid Malignancies, Warsaw, Poland

[4] Charles Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[5] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[6] Univ Manchester, Manchester, Lancs, England

[7] Christie NHS Fdn Trust, Manchester, Lancs, England

[8] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[9] Ctr Hosp Univ Reg Lille, Lille, France

[10] Fed Med Res Ctr, St Petersburg, Russia

[11] Derriford Hosp, Dept Hematol, Plymouth PL6 8DH, Devon, England

[12] Celgene Sarl, Boudry, Switzerland

[13] Celgene Corp, Summit, NJ USA

[14] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Lisbon, Portugal

[15] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy

[16] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8547

引用

页数：1

共 50 条

[41] Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
Goy, Andre
Sinha, Rajni
Williams, Michael E.
Besisik, Sevgi Kalayoglu
Drach, Johannes
Ramchandren, Radhakrishnan
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Witzig, Thomas E.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3688 - +
[42] Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study
Goy, Andre
Williams, Michael E.
Besisik, Sevgi Kalayoglu
Drach, Johannes
Ramchandren, Radhakrishnan
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Witzig, Thomas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S141 - S142
[43] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
Jerkeman, Mats
Hutchings, Martin
Raty, Riikka
Wader, Karin Fahl
Laurell, Anna
Kuitunen, Hanne
Toldbod, Helle
Pedersen, Lone Bredo
Eskelund, Christian Winther
Gronbaek, Kirsten
Niemann, Carsten Utoft
Geisler, Christian H.
Kolstad, Arne
BLOOD, 2016, 128 (22)
[44] Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
Morschhauser, Franck
Bouabdallah, Kamal
Stilgenbauer, Stephan
Thieblemont, Catherine
de Guibert, Sophie
Zettl, Florian
Gelbert, Lawrence M.
Turner, P. Kellie
Kambhampati, Siva Rama Prasad
Li, Li
Li, Lily Q.
Buchanan, Sean
Barriga, Susana
Bear, Melissa M.
Wilhelm, Martin
Hess, Georg
HAEMATOLOGICA, 2021, 106 (03) : 859 - 862
[45] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
Phillips, Tycel Jovelle
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Crump, Michael
Trneny, Marek
Bartlett, Nancy L.
Zaucha, Jan
Wrobel, Tomasz
Offner, Fritz
Humphrey, Kathryn
Relf, James
de L'Etang, Audrey Filezac
Carlile, David J.
Byrne, Ben
Qayum, Naseer
Lundberg, Linda
Dickinson, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
[46] Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
Lee, Hun Ju
Romaguera, Jorge E.
Feng, Lei
Desai, Aakash P.
Zhang, Liang
Fanale, Michelle
Samaniego, Felipe
Hagemeister, Fredrick B.
Fayad, Luis E.
Rodriguez, Maria A.
Medeiros, Jeffrey L.
Hartig, Kimberly
Nomie, Krystle
Ahmed, Makhdum
Badillo, Maria
Ye, Haige
Oki, Yasuhiro
Lin, Pei
Nastoupil, Loretta
Westin, Jason
Wang, Michael
ONCOLOGIST, 2017, 22 (05): : 549 - 553
[47] Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Kirschbaum, Mark
Frankel, Paul
Popplewell, Leslie
Zain, Jasmine
Delioukina, Maria
Pullarkat, Vinod
Matsuoka, Deron
Pulone, Bernadette
Rotter, Arnold J.
Espinoza-Delgado, Igor
Nademanee, Auayporn
Forman, Stephen J.
Gandara, David
Newman, Edward
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1198 - 1203
[48] Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma
Goy, Andre
Feldman, Tatyana A.
Leslie, Lori A.
Panchal, Rima Panchal
Nyirenda, Themba
Skarbnik, Alan P.
Yannotti, Kara
Zenreich, Joshua
Bejot, Colleen M.
Stives, Susan
Chow, Kar Fai
Bhattacharyya, Pritish K.
Yang, Xiao
Richards, Ernest
BLOOD, 2017, 130
[49] Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study
Phillips, Tycel Jovelle
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Crump, Michael
Trneny, Marek
Bartlett, Nancy L.
Zaucha, Jan
Wrobel, Tomasz
Offner, Fritz
de L'Etang, Audrey Filezac
Relf, James
Carlile, David J.
Byrne, Ben
Mulvihill, Estefania
Lundberg, Linda
Dickinson, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] Phase II study of Yttrium 90 (90Y) lbritumomab tiuxetan (Zevalin®) in patients with relapsed and refractory mantle cell lymphoma (MCL).
Wang, Michael
Oki, Yasuhiro
Pro, Barbara
Romaguera, Jorge Enrique
Rodriguez, Maria Alma
Samaniego, Felipe
McLaughlin, Peter
Hagemeister, Frederick
Neelapu, Sattva
Podoloff, Donald
Samuels, Barry
Loyer, Evelyne
Zhou, Yuhong
Younes, Anas
BLOOD, 2006, 108 (11) : 767A - 767A

← 1 2 3 4 5 →